Research analysts at StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a research note issued on Monday. The brokerage set a “sell” rating on the stock.
Navidea Biopharmaceuticals Stock Performance
NAVB stock opened at $0.00 on Monday. The stock’s 50 day moving average price is $0.01 and its 200 day moving average price is $0.03. The firm has a market cap of $100,084.00, a P/E ratio of -0.02 and a beta of 1.49. Navidea Biopharmaceuticals has a 1 year low of $0.00 and a 1 year high of $0.15.
About Navidea Biopharmaceuticals
Featured Stories
- Five stocks we like better than Navidea Biopharmaceuticals
- Manufacturing Stocks Investing
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- Most Volatile Stocks, What Investors Need to Know
- Lowe’s Stock: Hold Now, Buy it When it Dips
- What is the Euro STOXX 50 Index?
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.